Clinical Trials · NCT00005906
Treatment With Octreotide in Patients With Lymphangioleiomyomatosis
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- Enrollment
- 4
- Start date
- Jun 2000
- Locations
- 1 site, United States
- Primary endpoint
- Number of Participants With a Reduction in Total Tumor Volume of at Least 20%.